8 Best Hematology Startups to Watch in 2026

The Definitive Seedtable Ranking of Hematology Startups

We track 71,000+ companies and rank them dynamically using our Seedtable Score – a score that uses quantitative and qualitative data points to signal the momentum behind a company. We then monitor the list manually leveraging our expertise as founders and investors.

There are 8 start-ups with an aggregate funding of $2.5b. The average funding per company in this subset is $311.0m.

Last update to the database: Apr 7, 2026. See changelog.

Track over 71,000 companies

Discover
Fast-growing Global startups

Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.

Pricing + Sign up

8

Funding Rounds

$967.6m

Money raised

Freenome is a San Francisco-based company which uses genetic analysis for early cancer detection and risk assessment.

3

Funding Rounds

$1.4b

Money raised

Resilience Technology Corporation is an Hanover, Maryland-based cybersecurity company developing and manufacturing cyber security tools and founded in 1995.

Key people:

3

Funding Rounds

$28.5m

Money raised

AI-powered, FDA-cleared blood cell morphology platform replaces manual lab microscopy, helping hematologists and hematopathologists to detect cancers and blood-related diseases.

Location:

Key people:

1

Funding Rounds

$8.0m

Money raised

FYR Diagnostics is a Missoula, Montana-based company providing blood-based diagnostics, DNA and RNA amplification tools, and agriculture disease detection tools.

1

Funding Rounds

$30.0m

Money raised

A biotechnology company developing treatments for hematology and oncology diseases

10

Funding Rounds

$13.5m

Money raised

NuvOx Pharma is an oxygen therapeutics company founded in 2008 by David Wilson.

2

Funding Rounds

$4.8m

Money raised

The Hemarina technological platform is based on the peculiarities of the purified hemoglobin of lugworms, Arenicola marina . Its structure is comparable to that of human hemoglobin, however it is distinguished by: its extracellular character (it is not contained in a red blood cell), and therefore universal (compatibility with all blood groups) its ability to bind 40 times more oxygen than human hemoglobin its particularly small size: 250 times smaller than the human red blood cell

1

Funding Rounds

$1.0m

Money raised

Sanguine is a company that has the mission to accelerate medical research by eliminating the barriers to patient participation.

Sign up to access our full database

Enter your email and get access to 71,000 + technology companies you can partner with.

Join 29000+ founders, operators, and investors.